Science

Mar 15, 2025, 09:06

Myeloma Paper of the Day, March 15th, suggested by Robert Orlowski

Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Study of patient-reported outcomes and survival and adverse events in daratumumab-treated myeloma finds (surprisingly!) low physical function patients experienced greater OS and PFS benefit.”

“Predictive and Prognostic Significance of Patient-Reported Outcomes for Survival and Adverse Events in Daratumumab-Treated Multiple Myeloma”

Authors: Ahmad Abuhelwa, Sara Almansour, Ethan Basch, Humaid Al-Shamsi, Ziad Abuhelwa, Yasser Bustanji, Mohammad Semreen, Zelal Kharaba, Salma Ali, Rawan Mohamed, Ganessan Kichenadasse, Ross McKinnon, Michael Sorich, Karem Alzoubi, Ashley Hopkins.

More posts featuring Robert Orlowski.

Ahmad Abuhelwa Ashley Hopkins cancer daratumumab-treated myeloma Ethan Basch Ganessan Kichenadasse Humaid Al-Shamsi Karem Alzoubi Michael Sorich multiple myeloma Myeloma Paper of the Day OncoDaily Oncology Robert Orlowski Ross McKinnon Sara Almansour Ziad Abuhelwa

Audrey Evans - mother of neuroblastoma, a force for good in the world

New Paper Alert: Management of Immune Checkpoint Inhibitor-Associated Toxicities in Older Adults with Cancer

Kimryn Rathmell was Awarded 2025 ACS Medal of Honor

VERITAC-2 Trial Update: Vepdegestrant Meets Primary Endpoint in ESR1-Mutant Breast Cancer

New Paper Alert: HARMONi-2 study of Ivonescimab vs pembrolizumab for PD-L1-positive non-small cell lung cancer